D L Carlson Investment Group Inc. Purchases New Holdings in Repligen Corporation $RGEN

D L Carlson Investment Group Inc. acquired a new position in Repligen Corporation (NASDAQ:RGEN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,098 shares of the biotechnology company’s stock, valued at approximately $559,000.

Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 31.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC bought a new position in Repligen in the 3rd quarter valued at $368,387,000. Opti Capital Management LP bought a new position in Repligen in the 4th quarter valued at $2,399,209,000. Wasatch Advisors LP grew its position in Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after acquiring an additional 346,720 shares during the last quarter. Finally, Maverick Capital Ltd. purchased a new stake in Repligen in the first quarter worth $178,946,000. Institutional investors own 97.64% of the company’s stock.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.60% of the company’s stock.

Repligen Stock Performance

Shares of Repligen stock opened at $180.29 on Friday. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average price is $146.14 and its 200-day moving average price is $131.54. The firm has a market cap of $10.18 billion, a P/E ratio of 246.97, a P/E/G ratio of 3.22 and a beta of 1.03. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $188.73.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts expect that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada initiated coverage on shares of Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price for the company. Wolfe Research assumed coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target on the stock. Wells Fargo & Company lifted their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. HSBC lowered their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.